Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers
A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers

NCT01363999

CompletedPhase 1

Sponsor: Hoffmann-La Roche

Conditions: Healthy Volunteer

Interventions: atorvastatin, dalcetrapib

Countries: New Zealand

A single-center, crossover study to evaluate the pharmacokinetics of dalcetrapib and atorvastatin from prototype fixed dose combination formulations in healthy volunteers. Volunteers will receive a single dose of dalcetrapib with atorvastatin in each of four treatment periods.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Healthy volunteers, 18 to 55 years of age, inclusive

Exclusion Criteria:

* Any concomitant disease or ongoing condition that in the investigator's opinion could interfere with the study or could pose an unacceptable risk to the patient
* Clinically significant abnormal laboratory values
Locations (1)
  • Christchurch, New Zealand